IRF2BP2 and gastric cancer: Furthermore, the clinical follow‐up data for patients with GC indicated that high IRF2BP2 expression contributed to poor OS (P = .0057) (Figure 2C), and the 5‐year survival rate was comparatively higher in patients with lower IRF2BP2 expression (Table S1).